Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Lupin launches Luforbec inhaler in Spain
In collaboration with ERN
Lupin partners with Spain's ERN for launch of asthma, COPD inhaler Luforbec
Lupin has announced a strategic collaboration with Spanish pharmaceutical company Laboratorios ERN S.A. for the launch of Luforbec (beclometasone/formoterol) 100/6, a fixed-dose combination inhaler.
Lupin gains after receiving USFDA nod for Ranluspec
Lupin advanced 1.68% to Rs 2,286.50 after the company announced that the United States Food and Drug Administration (USFDA) has approved its ranibizumab, Ranluspec (ranibizumab-hkdz) injection.
Lupin receives USFDA approval for ranluspec biosimilar referencing Lucentis
Shares of Lupin Ltd ended at ₹2,251.00, down by ₹10.05, or 0.44%, on the BSE.
Lupin and alliance partner Natco receive USFDA approval for Eribulin Mesylate Injection
Lupin and its alliance partner Natco Pharma (Natco) today announced the approval from the United States Food and Drug Administration (U.S. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.
Four pharma stocks that should be on your radar today
Wockhardt received USFDA approval for its antibiotic Zaynich, a drug the company believes could generate annual sales of $1 billion to $2 billion globally. Lupin secured USFDA approval for the generic version of Sutab and will enjoy 180 days of marketing exclusivity in the US market.
Stocks to Watch for June 1: IndiGo, Glenmark Pharma, Lupin, NMDC, textile stocks and more
A host of stocks will be in focus on June 1, including IndiGo after its quarterly loss, Glenmark Pharma on strong earnings, Lupin following a US FDA approval, and NMDC after reporting robust revenue growth. Textile stocks may also attract attention after the Centre exempted customs duty on cotton imports until October-end to support the domestic textile industry.
Lupin gets US approval for colonoscopy prep drug, wins 180-day exclusivity
Lupin said it has received approval from the United States Food and Drug Administration (US FDA) for its abbreviated new drug application for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets, 1.479 g/0.225 g/0.188 g.
Stocks to Watch today: RIL, Lupin, Wipro, Asian Paints, Ireda,Tata Elxsi
Stocks to Watch today, May 29, 2026: Ashok Leyland, Alkem Laboratories, PhysicsWallah, GMR Airports, InterGlobe Aviation, NMDC, and Glenmark Pharma are among the top stocks to remain in focus today
Six pharma stocks that should be on your radar today over various news triggers
It was a busy weekend for pharma stocks as four of them — Divi's Laboratories, Fortis Healthcare, Torrent Pharma and Narayana Hrudayalaya — reported their quarterly results. Meanwhile, Lupin marked its entry into the Chinese market, while Glenmark Pharma's US arm settled an anti-trust litigation. Here's a look at these names in detail:
Stocks to Watch for May 25: Hindalco, Eicher Motors, Divi's Labs, Torrent Pharma, Lupin and more
From result reactions coming from Hindalco, Divi's Labs, Eicher Motors, JK Cement, Torrent Pharma and many others, to Glenmark settling patent litigations and oil sensitives due to the US-Iran developments will be some of the important stocks that should be on your radar going into Monday's trade on May 25.
Lupin gets approval to launch flu medicine in China, enters Chinese market for first time
Lupin has received approval in China for its flu treatment Oseltamivir oral suspension, marking the company’s first product launch in the Chinese market.